Diabetes - SF-1019 Receives Approval For Treatment, Marketing And Distribution In Mal

[A D]

Immunosyn Corporation (OTCBB:IMYN) announced today that marketing, distribution and patient treatment approval has been granted by the Ministry of Health Malaysia for SF-1019 in the Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia will be R-1818.

More...

 

[davidwest]

nice tip...

very interesting, especially the " SF-1019 was developed from extensive research into Biological Response Modifiers (BRMs)..." quote.

a concept that could really change medicine...

thanks
d